 | • レポートコード：MRC2-11QY12298 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は特発性肺線維症（IPF）のグローバル市場について調査・分析したレポートです。種類別（全身性コルチコステロイド、免疫抑制薬、チロシンキナーゼ阻害剤、抗線維化剤）市場規模、用途別（病院、クリニック、外来手術センター、学術・研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別特発性肺線維症（IPF）の競争状況、市場シェア ・世界の特発性肺線維症（IPF）市場：種類別市場規模 2015年-2020年（全身性コルチコステロイド、免疫抑制薬、チロシンキナーゼ阻害剤、抗線維化剤） ・世界の特発性肺線維症（IPF）市場：種類別市場規模予測 2021年-2026年（全身性コルチコステロイド、免疫抑制薬、チロシンキナーゼ阻害剤、抗線維化剤） ・世界の特発性肺線維症（IPF）市場：用途別市場規模 2015年-2020年（病院、クリニック、外来手術センター、学術・研究機関） ・世界の特発性肺線維症（IPF）市場：用途別市場規模予測 2021年-2026年（病院、クリニック、外来手術センター、学術・研究機関） ・北米の特発性肺線維症（IPF）市場分析：米国、カナダ ・ヨーロッパの特発性肺線維症（IPF）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの特発性肺線維症（IPF）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の特発性肺線維症（IPF）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの特発性肺線維症（IPF）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：MediciNova、Boehringer Ingelheim、F. Hoffmann-La Roche、FibroGen、Promedior、Merck、Galapagos、Prometic Life Sciences、Cipla ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.
An increase in the incidence and prevalence of fibrotic diseases is the primary driver for the growth of this market. Idiopathic pulmonary fibrosis most commonly affects middle-aged to older adults and is characterized by the scarring of lung tissues. In older people, these scars tend to build up and affect the normal functioning of lungs. Thus, an increase in aging population leads to increased prevalence of the disease, which in turn results in market growth during the predicted period.
Market Analysis and Insights: Global Idiopathic Pulmonary Fibrosis Market
The global Idiopathic Pulmonary Fibrosis market size is projected to reach US$ 1785.2 million by 2026, from US$ 1618.8 million in 2020, at a CAGR of 9.5%% during 2021-2026.
Global Idiopathic Pulmonary Fibrosis Scope and Market Size
Idiopathic Pulmonary Fibrosis market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Idiopathic Pulmonary Fibrosis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
MediciNova
Boehringer Ingelheim
F. Hoffmann-La Roche
FibroGen
Promedior
Merck
Galapagos
Prometic Life Sciences
Cipla
Market segment by Type, the product can be split into
Systemic Corticosteroids
Immunosuppressant Drugs
Tyrosine Kinase Inhibitors
Antifibrotic Agents
Market segment by Application, split into
Hospitals
Clinics
Ambulatory Surgical Centers
Academic and Research Organizations
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Idiopathic Pulmonary Fibrosis Revenue
1.4 Market by Type
1.4.1 Global Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Systemic Corticosteroids
1.4.3 Immunosuppressant Drugs
1.4.4 Tyrosine Kinase Inhibitors
1.4.5 Antifibrotic Agents
1.5 Market by Application
1.5.1 Global Idiopathic Pulmonary Fibrosis Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Ambulatory Surgical Centers
1.5.5 Academic and Research Organizations
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Idiopathic Pulmonary Fibrosis Market Perspective (2015-2026)
2.2 Global Idiopathic Pulmonary Fibrosis Growth Trends by Regions
2.2.1 Idiopathic Pulmonary Fibrosis Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Idiopathic Pulmonary Fibrosis Historic Market Share by Regions (2015-2020)
2.2.3 Idiopathic Pulmonary Fibrosis Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Idiopathic Pulmonary Fibrosis Market Growth Strategy
2.3.6 Primary Interviews with Key Idiopathic Pulmonary Fibrosis Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Idiopathic Pulmonary Fibrosis Players by Market Size
3.1.1 Global Top Idiopathic Pulmonary Fibrosis Players by Revenue (2015-2020)
3.1.2 Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Players (2015-2020)
3.1.3 Global Idiopathic Pulmonary Fibrosis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Idiopathic Pulmonary Fibrosis Market Concentration Ratio
3.2.1 Global Idiopathic Pulmonary Fibrosis Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Idiopathic Pulmonary Fibrosis Revenue in 2019
3.3 Idiopathic Pulmonary Fibrosis Key Players Head office and Area Served
3.4 Key Players Idiopathic Pulmonary Fibrosis Product Solution and Service
3.5 Date of Enter into Idiopathic Pulmonary Fibrosis Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Idiopathic Pulmonary Fibrosis Historic Market Size by Type (2015-2020)
4.2 Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020)
5.2 Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Idiopathic Pulmonary Fibrosis Market Size (2015-2020)
6.2 Idiopathic Pulmonary Fibrosis Key Players in North America (2019-2020)
6.3 North America Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020)
6.4 North America Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020)
7 Europe
7.1 Europe Idiopathic Pulmonary Fibrosis Market Size (2015-2020)
7.2 Idiopathic Pulmonary Fibrosis Key Players in Europe (2019-2020)
7.3 Europe Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020)
7.4 Europe Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020)
8 China
8.1 China Idiopathic Pulmonary Fibrosis Market Size (2015-2020)
8.2 Idiopathic Pulmonary Fibrosis Key Players in China (2019-2020)
8.3 China Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020)
8.4 China Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020)
9 Japan
9.1 Japan Idiopathic Pulmonary Fibrosis Market Size (2015-2020)
9.2 Idiopathic Pulmonary Fibrosis Key Players in Japan (2019-2020)
9.3 Japan Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020)
9.4 Japan Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Idiopathic Pulmonary Fibrosis Market Size (2015-2020)
10.2 Idiopathic Pulmonary Fibrosis Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020)
10.4 Southeast Asia Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020)
11 India
11.1 India Idiopathic Pulmonary Fibrosis Market Size (2015-2020)
11.2 Idiopathic Pulmonary Fibrosis Key Players in India (2019-2020)
11.3 India Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020)
11.4 India Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Idiopathic Pulmonary Fibrosis Market Size (2015-2020)
12.2 Idiopathic Pulmonary Fibrosis Key Players in Central & South America (2019-2020)
12.3 Central & South America Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020)
12.4 Central & South America Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 MediciNova
13.1.1 MediciNova Company Details
13.1.2 MediciNova Business Overview
13.1.3 MediciNova Idiopathic Pulmonary Fibrosis Introduction
13.1.4 MediciNova Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020))
13.1.5 MediciNova Recent Development
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Details
13.2.2 Boehringer Ingelheim Business Overview
13.2.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Introduction
13.2.4 Boehringer Ingelheim Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020)
13.2.5 Boehringer Ingelheim Recent Development
13.3 F. Hoffmann-La Roche
13.3.1 F. Hoffmann-La Roche Company Details
13.3.2 F. Hoffmann-La Roche Business Overview
13.3.3 F. Hoffmann-La Roche Idiopathic Pulmonary Fibrosis Introduction
13.3.4 F. Hoffmann-La Roche Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020)
13.3.5 F. Hoffmann-La Roche Recent Development
13.4 FibroGen
13.4.1 FibroGen Company Details
13.4.2 FibroGen Business Overview
13.4.3 FibroGen Idiopathic Pulmonary Fibrosis Introduction
13.4.4 FibroGen Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020)
13.4.5 FibroGen Recent Development
13.5 Promedior
13.5.1 Promedior Company Details
13.5.2 Promedior Business Overview
13.5.3 Promedior Idiopathic Pulmonary Fibrosis Introduction
13.5.4 Promedior Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020)
13.5.5 Promedior Recent Development
13.6 Merck
13.6.1 Merck Company Details
13.6.2 Merck Business Overview
13.6.3 Merck Idiopathic Pulmonary Fibrosis Introduction
13.6.4 Merck Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020)
13.6.5 Merck Recent Development
13.7 Galapagos
13.7.1 Galapagos Company Details
13.7.2 Galapagos Business Overview
13.7.3 Galapagos Idiopathic Pulmonary Fibrosis Introduction
13.7.4 Galapagos Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020)
13.7.5 Galapagos Recent Development
13.8 Prometic Life Sciences
13.8.1 Prometic Life Sciences Company Details
13.8.2 Prometic Life Sciences Business Overview
13.8.3 Prometic Life Sciences Idiopathic Pulmonary Fibrosis Introduction
13.8.4 Prometic Life Sciences Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020)
13.8.5 Prometic Life Sciences Recent Development
13.9 Cipla
13.9.1 Cipla Company Details
13.9.2 Cipla Business Overview
13.9.3 Cipla Idiopathic Pulmonary Fibrosis Introduction
13.9.4 Cipla Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020)
13.9.5 Cipla Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Idiopathic Pulmonary Fibrosis Key Market Segments
Table 2. Key Players Covered: Ranking by Idiopathic Pulmonary Fibrosis Revenue
Table 3. Ranking of Global Top Idiopathic Pulmonary Fibrosis Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Systemic Corticosteroids
Table 6. Key Players of Immunosuppressant Drugs
Table 7. Key Players of Tyrosine Kinase Inhibitors
Table 8. Key Players of Antifibrotic Agents
Table 9. Global Idiopathic Pulmonary Fibrosis Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Idiopathic Pulmonary Fibrosis Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Idiopathic Pulmonary Fibrosis Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Idiopathic Pulmonary Fibrosis Market Share by Regions (2015-2020)
Table 13. Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Idiopathic Pulmonary Fibrosis Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Idiopathic Pulmonary Fibrosis Market Growth Strategy
Table 19. Main Points Interviewed from Key Idiopathic Pulmonary Fibrosis Players
Table 20. Global Idiopathic Pulmonary Fibrosis Revenue by Players (2015-2020) (Million US$)
Table 21. Global Idiopathic Pulmonary Fibrosis Market Share by Players (2015-2020)
Table 22. Global Top Idiopathic Pulmonary Fibrosis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Pulmonary Fibrosis as of 2019)
Table 23. Global Idiopathic Pulmonary Fibrosis by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Idiopathic Pulmonary Fibrosis Product Solution and Service
Table 26. Date of Enter into Idiopathic Pulmonary Fibrosis Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020) (Million US$)
Table 29. Global Idiopathic Pulmonary Fibrosis Market Size Share by Type (2015-2020)
Table 30. Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Type (2021-2026)
Table 31. Global Idiopathic Pulmonary Fibrosis Market Size Share by Application (2015-2020)
Table 32. Global Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020) (Million US$)
Table 33. Global Idiopathic Pulmonary Fibrosis Market Size Share by Application (2021-2026)
Table 34. North America Key Players Idiopathic Pulmonary Fibrosis Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Idiopathic Pulmonary Fibrosis Market Share (2019-2020)
Table 36. North America Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020) (Million US$)
Table 37. North America Idiopathic Pulmonary Fibrosis Market Share by Type (2015-2020)
Table 38. North America Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020) (Million US$)
Table 39. North America Idiopathic Pulmonary Fibrosis Market Share by Application (2015-2020)
Table 40. Europe Key Players Idiopathic Pulmonary Fibrosis Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Idiopathic Pulmonary Fibrosis Market Share (2019-2020)
Table 42. Europe Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Idiopathic Pulmonary Fibrosis Market Share by Type (2015-2020)
Table 44. Europe Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Idiopathic Pulmonary Fibrosis Market Share by Application (2015-2020)
Table 46. China Key Players Idiopathic Pulmonary Fibrosis Revenue (2019-2020) (Million US$)
Table 47. China Key Players Idiopathic Pulmonary Fibrosis Market Share (2019-2020)
Table 48. China Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020) (Million US$)
Table 49. China Idiopathic Pulmonary Fibrosis Market Share by Type (2015-2020)
Table 50. China Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020) (Million US$)
Table 51. China Idiopathic Pulmonary Fibrosis Market Share by Application (2015-2020)
Table 52. Japan Key Players Idiopathic Pulmonary Fibrosis Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Idiopathic Pulmonary Fibrosis Market Share (2019-2020)
Table 54. Japan Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Idiopathic Pulmonary Fibrosis Market Share by Type (2015-2020)
Table 56. Japan Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Idiopathic Pulmonary Fibrosis Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Idiopathic Pulmonary Fibrosis Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Idiopathic Pulmonary Fibrosis Market Share (2019-2020)
Table 60. Southeast Asia Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Idiopathic Pulmonary Fibrosis Market Share by Type (2015-2020)
Table 62. Southeast Asia Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Idiopathic Pulmonary Fibrosis Market Share by Application (2015-2020)
Table 64. India Key Players Idiopathic Pulmonary Fibrosis Revenue (2019-2020) (Million US$)
Table 65. India Key Players Idiopathic Pulmonary Fibrosis Market Share (2019-2020)
Table 66. India Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020) (Million US$)
Table 67. India Idiopathic Pulmonary Fibrosis Market Share by Type (2015-2020)
Table 68. India Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020) (Million US$)
Table 69. India Idiopathic Pulmonary Fibrosis Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Idiopathic Pulmonary Fibrosis Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Idiopathic Pulmonary Fibrosis Market Share (2019-2020)
Table 72. Central & South America Idiopathic Pulmonary Fibrosis Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Idiopathic Pulmonary Fibrosis Market Share by Type (2015-2020)
Table 74. Central & South America Idiopathic Pulmonary Fibrosis Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Idiopathic Pulmonary Fibrosis Market Share by Application (2015-2020)
Table 76. MediciNova Company Details
Table 77. MediciNova Business Overview
Table 78. MediciNova Product
Table 79. MediciNova Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020) (Million US$)
Table 80. MediciNova Recent Development
Table 81. Boehringer Ingelheim Company Details
Table 82. Boehringer Ingelheim Business Overview
Table 83. Boehringer Ingelheim Product
Table 84. Boehringer Ingelheim Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020) (Million US$)
Table 85. Boehringer Ingelheim Recent Development
Table 86. F. Hoffmann-La Roche Company Details
Table 87. F. Hoffmann-La Roche Business Overview
Table 88. F. Hoffmann-La Roche Product
Table 89. F. Hoffmann-La Roche Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020) (Million US$)
Table 90. F. Hoffmann-La Roche Recent Development
Table 91. FibroGen Company Details
Table 92. FibroGen Business Overview
Table 93. FibroGen Product
Table 94. FibroGen Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020) (Million US$)
Table 95. FibroGen Recent Development
Table 96. Promedior Company Details
Table 97. Promedior Business Overview
Table 98. Promedior Product
Table 99. Promedior Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020) (Million US$)
Table 100. Promedior Recent Development
Table 101. Merck Company Details
Table 102. Merck Business Overview
Table 103. Merck Product
Table 104. Merck Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020) (Million US$)
Table 105. Merck Recent Development
Table 106. Galapagos Company Details
Table 107. Galapagos Business Overview
Table 108. Galapagos Product
Table 109. Galapagos Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020) (Million US$)
Table 110. Galapagos Recent Development
Table 111. Prometic Life Sciences Business Overview
Table 112. Prometic Life Sciences Product
Table 113. Prometic Life Sciences Company Details
Table 114. Prometic Life Sciences Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020) (Million US$)
Table 115. Prometic Life Sciences Recent Development
Table 116. Cipla Company Details
Table 117. Cipla Business Overview
Table 118. Cipla Product
Table 119. Cipla Revenue in Idiopathic Pulmonary Fibrosis Business (2015-2020) (Million US$)
Table 120. Cipla Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Idiopathic Pulmonary Fibrosis Market Share by Type: 2020 VS 2026
Figure 2. Systemic Corticosteroids Features
Figure 3. Immunosuppressant Drugs Features
Figure 4. Tyrosine Kinase Inhibitors Features
Figure 5. Antifibrotic Agents Features
Figure 6. Global Idiopathic Pulmonary Fibrosis Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Ambulatory Surgical Centers Case Studies
Figure 10. Academic and Research Organizations Case Studies
Figure 11. Idiopathic Pulmonary Fibrosis Report Years Considered
Figure 12. Global Idiopathic Pulmonary Fibrosis Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Idiopathic Pulmonary Fibrosis Market Share by Regions: 2020 VS 2026
Figure 14. Global Idiopathic Pulmonary Fibrosis Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Idiopathic Pulmonary Fibrosis Market Share by Players in 2019
Figure 17. Global Top Idiopathic Pulmonary Fibrosis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Pulmonary Fibrosis as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Idiopathic Pulmonary Fibrosis Revenue in 2019
Figure 19. North America Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
全身性特発性若年性関節炎治療の世界市場（～2026年） Market Analysis and Insights: Global Systemic Idiopathic Juvenile Arthritis Treatment Market The global Systemic Idiopathic Juvenile Arthritis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Systemic Idiopath…- 慢性特発性骨髄線維症の世界市場（～2026年） Idiopathic myelofibrosis is a chronic myelo-proliferative disorder and characterized by abnormal mutation of stem cells. This abnormal mutation of stem cells and excessive production of platelets result in development of fibrous tissues within the bone-marrow. This factor would ultimately negatively…
- 嚢胞性線維症（ムコビスコイドーシス）検査の世界市場（～2026年） Cystic Fibrosis, also known as mucoviscoidosis, is an inherited genetic disorder that affects the secretory glands, including mucus and sweat glands. It mainly affects the lungs and digestive system. An individual suffering from cystic fibrosis show characteristic symptoms, such as, secretion of thi…
- 慢性特発性便秘（CIC）治療薬の世界市場（～2026年） Chronic idiopathic constipation (CIC) is a health condition in which a person experiences chronic symptoms of constipation, yet no visible cause can be identified through standard diagnostic testing. The term idiopathic is used because it means there is no known cause. CIC includes symptoms of diffi…
- 肺動脈性肺高血圧症（PAH）の世界市場（～2026年） Market Analysis and Insights: Global Pulmonary Arterial Hypertension (PAH) Market The global Pulmonary Arterial Hypertension (PAH) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Pulmonary Arterial Hypertension (PAH) S…